Evaluation of the ability of pinostrobin against methicillin-resistant Staphylococcus aureus from Syzygium glomeratum extract

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA), the most common pathogen in hospital and community environments, can cause serious and even fatal infections. Pinostrobin is isolated from the ethanol extract of Syzygium glomeratum, which has anti-MRSA activity. This research was conducted with the purpose of evaluating the anti-MRSA activity of pinostrobin. The checkerboard method was used for the determination of synergism between pinostrobin and vancomycin in anti-MRSA activity. The results show that pinostrobin has the ability to synergise with vancomycin anti-MRSA through the fractional inhibitory concentration index FIC index equals 0.5. The crystal violet-based assay is used to evaluate the MRSA biofilm formation of pinostrobin. The results show that the pinostrobin did not cause inhibition of MRSA biofilm formation. Using the PBP2a latex agglutination test to determine the absence of PBP2a protein when MRSA was grown in culture medium-supplied pinostrobin shows
that pinostrobin inhibited the expression of PBP2a protein in the cell wall of MRSA. Pinostrobin was purified from the Syzygium genus, which has the potency of anti-MRSA activity and the synergism with vancomycin, initially processing the inhibition of expression PBP2a protein in the cell wall of MRSA.